{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T08:58:53Z","timestamp":1764665933592,"version":"3.46.0"},"reference-count":28,"publisher":"Scientific Scholar","content-domain":{"domain":["nmji.in"],"crossmark-restriction":true},"short-container-title":["NMJI"],"abstract":"<jats:sec id=\"st1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Transmission of the delta variant resulted in a surge of SARS-CoV-2 cases in New Delhi, India, during the early half of the year 2021. Healthcare workers (HCWs) received vaccines on priority for the prevention of infection. We estimated the effectiveness of the BBV152 vaccine among HCWs against SARS-CoV-2 infection, hospitalization, or death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"st2\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study was done at a multi-speciality tertiary care public-funded hospital in New Delhi, India. 12 237 HCWs participated in the study. The intervention was the BBV152 whole virion inactivated vaccine (Covaxin, Bharat Biotech Limited, Hyderabad, administered two doses four weeks apart). The outcome measures were vaccine effectiveness against any SARS-CoV-2 infection, symptomatic infection, or hospitalization or death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"st3\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean (SD) age of HCWs was 36 (11) years, 66% were men, and 16% had comorbid conditions. After adjusting for potential covariates\u2014age, sex, health worker type category, body mass index, and comorbid conditions, the vaccine effectiveness (95% confidence interval) in fully vaccinated HCWs and &gt;14 days after receipt of the second dose was 44% (37 to 51, p&lt;0.001) against sympto-matic infection, hospitalization or death due to SARS-CoV-2, and 61% (37 to 76, p&lt;0.001) against hospitalization or death, respectively. The partial dose was not effective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"st4\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The BBV152 vaccine, with complete two doses, offered a modest response to SARS-CoV-2 infection in real-life situations against a backdrop of high delta variant community transmission.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.25259\/nmji_726_2022","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T11:01:25Z","timestamp":1764154885000},"page":"344-349","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of BBV152 vaccine against SARS-CoV-2 infections, hospitalizations and deaths among healthcare workers in the setting of high delta variant transmission in New Delhi, India"],"prefix":"10.25259","volume":"38","author":[{"given":"SUMIT","family":"MALHOTRA","sequence":"first","affiliation":[{"name":"Centre for Community Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KALAIVANI","family":"MANI","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RAKESH","family":"LODHA","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SAMEER","family":"BAKHSHI","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VIJAY PRAKASH","family":"MATHUR","sequence":"additional","affiliation":[{"name":"Division of Pedodontics and Preventive Dentistry, Centre for Dental Education and Research, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"POOJA","family":"GUPTA","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SAURABH","family":"KEDIA","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MARI JEEVA","family":"SANKAR","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PARMESHWAR","family":"KUMAR","sequence":"additional","affiliation":[{"name":"Department of Hospital Administration, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ARVIND","family":"KUMAR","sequence":"additional","affiliation":[{"name":"Department of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VINEET","family":"AHUJA","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SUBRATA","family":"SINHA","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India"},{"name":"National Science Chair awardee of the ANRF, India; NSC\/2022\/000054"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RANDEEP","family":"GULERIA","sequence":"additional","affiliation":[{"name":"Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"year":"2022","author":"World Health Organization","key":"10.25259\/NMJI_726_2022\/ref-1","unstructured":"Edition 98. Available at: www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19\u201429\u2013june-2022 (accessed on 5 Aug 2022)"},{"key":"10.25259\/NMJI_726_2022\/ref-4","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1126\/science.abj9932","article-title":"Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India","volume":"374","author":"Dhar","year":"2021","journal-title":"Science"},{"key":"10.25259\/NMJI_726_2022\/ref-5","article-title":"Ministry of Health and Family Welfare","author":"Government of India","year":"2022","journal-title":"Cumulative coverage report of COVID-19 vaccination"},{"key":"10.25259\/NMJI_726_2022\/ref-6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: A double-blind, randomised, phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.25259\/NMJI_726_2022\/ref-7","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/S0140-6736(21)02000-6","article-title":"Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomised, double-blind, controlled, phase 3 trial","volume":"398","author":"Ella","year":"2021","journal-title":"Lancet"},{"key":"10.25259\/NMJI_726_2022\/ref-8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.ijid.2022.07.033","article-title":"Effectiveness of BBV152\/Covaxin and AZD1222\/Covishield vaccines against severe COVID-19 and B.1.617.2\/Delta variant in India, 2021: A multi-centric hospital-based case-control study","volume":"122","author":"Bhatnagar","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.25259\/NMJI_726_2022\/ref-9","doi-asserted-by":"publisher","first-page":"n2034","DOI":"10.1136\/bmj.n2034","article-title":"Real world effectiveness of COVID-19 vaccines","volume":"374","author":"Hungerford","year":"2021","journal-title":"BMJ"},{"article-title":"COVID-19 vaccine breakthrough case investigation and reporting","year":"2021","author":"Centers for Disease Control and Prevention","key":"10.25259\/NMJI_726_2022\/ref-10"},{"issue":"1","key":"10.25259\/NMJI_726_2022\/ref-11","doi-asserted-by":"publisher","first-page":"e715","DOI":"10.1093\/cid\/ciab986","article-title":"Infection with the severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) Delta variant is associated with higher recovery of infectious virus compared to the Alpha variant in both unvaccinated and vaccinated individuals","volume":"75","author":"Luo","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.25259\/NMJI_726_2022\/ref-12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12916-021-02103-4","article-title":"Transmission event of SARS-CoV-2 Delta variant reveals multiple vaccine breakthrough infections","volume":"19","author":"Farinholt","year":"2021","journal-title":"BMC Med"},{"key":"10.25259\/NMJI_726_2022\/ref-13","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.mayocp.2021.06.003","article-title":"Protective effect of COVID-19 vaccine among healthcare workers during the second wave of the pandemic in India","volume":"96","author":"Victor","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.25259\/NMJI_726_2022\/ref-14","doi-asserted-by":"publisher","first-page":"S264","DOI":"10.1016\/j.mjafi.2021.06.032","article-title":"COVISHIELD (AZD1222) vaccine effectiveness among healthcare and frontline workers of Indian Armed Forces: Interim results of VIN-WIN cohort study","volume":"77","author":"Ghosh","year":"2021","journal-title":"Med J Armed Forces India"},{"key":"10.25259\/NMJI_726_2022\/ref-15","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"10.25259\/NMJI_726_2022\/ref-16","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S1473-3099(21)00674-5","article-title":"Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: A test-negative, case-control study","volume":"22","author":"Desai","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.25259\/NMJI_726_2022\/ref-17","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): Explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"key":"10.25259\/NMJI_726_2022\/ref-18","article-title":"Novel coronavirus COVID-19 therapeutic trial synopsis","author":"World Health Organization","year":"2020","journal-title":"WHO R&D Blueprint"},{"article-title":"National guidelines for ethics committees reviewing biomedical and health research during COVID-19 pandemic","year":"2020","author":"Indian Council of Medical Research","key":"10.25259\/NMJI_726_2022\/ref-19"},{"key":"10.25259\/NMJI_726_2022\/ref-20","doi-asserted-by":"publisher","first-page":"100025","DOI":"10.1016\/j.lana.2021.100025","article-title":"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study","volume":"1","author":"Hitchings","year":"2021","journal-title":"Lancet Reg Health Am"},{"key":"10.25259\/NMJI_726_2022\/ref-21","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1056\/NEJMoa2106599","article-title":"Effectiveness of mRNA Covid-19 vaccine among US healthcare personnel","volume":"385","author":"Pilishvili","year":"2021","journal-title":"N Engl J Med"},{"key":"10.25259\/NMJI_726_2022\/ref-22","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/S0140-6736(21)00790-X","article-title":"COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): A prospective, multicentre, cohort study","volume":"397","author":"Hall","year":"2021","journal-title":"Lancet"},{"key":"10.25259\/NMJI_726_2022\/ref-23","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.15585\/mmwr.mm7034e4","article-title":"Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (Delta) variant predominance-eight US locations, December 2020-August 2021","volume":"70","author":"Fowlkes","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.25259\/NMJI_726_2022\/ref-24","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/cid\/ciab411","article-title":"Neutralization of variant under investigation B.1.617.1 with sera of BBV152 vaccinees","volume":"74","author":"Yadav","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.25259\/NMJI_726_2022\/ref-25","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.1016\/j.vaccine.2021.09.055","article-title":"Antibody response after first and second dose of ChAdOx1-nCOV (Covishield) and BBV-152 (Covaxin) among healthcare workers in India: Final results of COVAT study","volume":"39","author":"Singh","year":"2021","journal-title":"Vaccine"},{"key":"10.25259\/NMJI_726_2022\/ref-26","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1056\/NEJMe2111165","article-title":"Effectiveness of an inactivated SARS-CoV-2 vaccine","volume":"385","author":"Wilder-Smith","year":"2021","journal-title":"N Engl J Med"},{"key":"10.25259\/NMJI_726_2022\/ref-27","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"10.25259\/NMJI_726_2022\/ref-28","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1002\/jmv.27461","article-title":"Variants of concern responsible for SARS-CoV-2 vaccine breakthrough infections from India","volume":"94","author":"Singh","year":"2022","journal-title":"J Med Virol"},{"key":"10.25259\/NMJI_726_2022\/ref-29","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41586-021-03944-y","article-title":"SARSCoV-2 B.1.617.2 Delta variant replication and immune evasion","volume":"599","author":"Mlcochova","year":"2021","journal-title":"Nature"},{"key":"10.25259\/NMJI_726_2022\/ref-30","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.3390\/v13091782","article-title":"Clinical characterization and genomic analysis of samples from COVID-19 breakthrough infections during the second wave among the various states of India","volume":"13","author":"Gupta","year":"2021","journal-title":"Viruses"}],"container-title":["The National Medical Journal of India"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/nmji.in\/effectiveness-of-bbv152-vaccine-against-sars-cov-2-infections-hospitalizations-and-deaths-among-healthcare-workers-in-the-setting-of-high-delta-variant-transmission-in-new-delhi-india\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nmji.in\/effectiveness-of-bbv152-vaccine-against-sars-cov-2-infections-hospitalizations-and-deaths-among-healthcare-workers-in-the-setting-of-high-delta-variant-transmission-in-new-delhi-india\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T08:54:05Z","timestamp":1764665645000},"score":1,"resource":{"primary":{"URL":"https:\/\/nmji.in\/effectiveness-of-bbv152-vaccine-against-sars-cov-2-infections-hospitalizations-and-deaths-among-healthcare-workers-in-the-setting-of-high-delta-variant-transmission-in-new-delhi-india\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":28,"alternative-id":["10.25259\/NMJI_726_2022"],"URL":"https:\/\/doi.org\/10.25259\/nmji_726_2022","relation":{},"ISSN":["2583-150X","0970-258X"],"issn-type":[{"type":"electronic","value":"2583-150X"},{"type":"print","value":"0970-258X"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"article-number":"344"}}